QRG Capital Management’s Novo Nordisk NVO Stock Holding History

QRG Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.4M	Buy	175,187 +32,756	+23%	+$1.41M	0.07%	232
2026 Q1	$5.23M	Buy	142,431 +32,145	+29%	+$1.52M	0.05%	273
2025 Q4	$5.61M	Sell	110,286 -19,045	-15%	-$974K	0.06%	232
2025 Q3	$7.18M	Sell	129,331 -103,385	-44%	-$6.05M	0.09%	197
2025 Q2	$16.1M	Buy	232,716 +1,480	+0.6%	+$101K	0.14%	150
2025 Q1	$16.1M	Sell	231,236 -20,600	-8%	-$1.7M	0.17%	139
2024 Q4	$21.7M	Buy	251,836 +2,032	+0.8%	+$220K	0.22%	94
2024 Q3	$29.7M	Buy	249,804 +6,844	+3%	+$913K	0.32%	67
2024 Q2	$34.7M	Buy	242,960 +9,964	+4%	+$1.32M	0.41%	48
2024 Q1	$29.9M	Buy	232,996 +5,821	+3%	+$693K	0.38%	55
2023 Q4	$23.5M	Buy	227,175 +29,587	+15%	+$2.93M	0.35%	62
2023 Q3	$18M	Buy	+197,588	New	+$17.4M	0.31%	76

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

QRG Capital Management's NVO Position: Q2 2026 in Review

QRG Capital Management increased its Novo Nordisk (NVO) stake by 23% in Q2 2026, buying an estimated $1.41M and bringing the position to 175,187 shares worth $8.4M. The position accounts for 0.07% of the portfolio, ranked #232.

QRG Capital Management first reported a position in NVO in Q3 2023 and has held it in 12 quarters since. The position peaked at $34.7M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

QRG Capital Management held 175,187 shares of Novo Nordisk worth $8.4M as of Q2 2026.
QRG Capital Management bought 32,756 Novo Nordisk shares in Q2 2026, an estimated $1.41M.
Novo Nordisk made up 0.07% of QRG Capital Management's portfolio in Q2 2026, its #232 holding.
QRG Capital Management first reported a position in Novo Nordisk in Q3 2023 and has held it in 12 quarters since.
QRG Capital Management's Novo Nordisk position peaked at $34.7M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.